GALECTIN THERAPEUTICS INC (GALT) Form 8-K — May 15, 2026

$GALTForm 8-KItems 2.02, 9.01Filed May 15, 2026, 7:50 AM ET0001140361-26-021496Original filing

Galectin Therapeutics reported Q1 2026 financial results showing a net loss of $5.1 million, a significant improvement from the $9.6 million loss in the same period last year. This reduction was driven primarily by a 65% decrease in R&D expenses to $2.2 million, reflecting the timing of expenditures related to the NAVIGATE clinical trial. The company highlighted positive biomarker data from its NAVIGATE Phase 2b/3 trial for belapectin in MASH cirrhosis, noting statistically significant reductions in liver stiffness measurements.

Key figures

Revenue: 0
Total Debt: 145996000
Total Assets: 15759000
Cash Position: 14111000
Rd expense q1 2025: 6485000
Rd expense q1 2026: 2231000
Shares outstanding: 65782000
Gna expense q1 2025: 1412000
Gna expense q1 2026: 1846000
Credit line available: 10000000

Price after filing

1 day: 0.0%7 days: +7.2%30 days: +11.1%

Close on the filing date to close N calendar days later (from $2.35). Historical, not a forecast.

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.